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Purpose/Objective: Permanent breast seed implantation 
(PBSI) is a brachytherapy technique where Pd-103 seeds are 
implanted directly into the clinical target volume (CTV). 
Seeds used in PBSI emit short range photons that confine 
exposure to the target tissue resulting in a high degree of 
dose conformality. However there are limitations such as; 
suboptimal dose distribution due to the inherent low photon 
energy (21 keV), or misplacement/migration of seeds, and 
inactive seeds left after treatment. To address these 
limitations we have investigated the application of gold 
nanoparticles (AuNPs), which studies have shown can be 
functionalized by binding radioisotopes and various 
monoclonal antibodies to its surface. Numerous studies have 
also suggested that AuNPs exhibit radiation enhancing 
properties. The goal of this research then is to design an 
unsealed seed comprising of Pd-103 radiolabeled AuNPs to 
enhance radiotherapy while improving dose uniformity 
through physical diffusion of radioactive nanoparticles. In this 
initial phase of the study, we outline the design of the AuNP 
seed and characterize AuNP release from the seed. 
Materials and Methods: Ultrapure medical grade sodium 
alginate (Pronova™ NovaMatrix, Norway) was initially tested 
to identify the concentration most suitable for forming seeds. 
Concentrated non-radioactive 30nm AuNPs (BBI Solutions, UK) 
were mixed with sodium alginate, and polymerized using 10% 
calcium chloride to form AuNP embedded seeds. To develop 
a model for nanoparticle release phantoms were implanted 
with seeds, followed by mice bearing MDA-MB-231 human 
adenocarcinoma breast xenografts. Seeds made with 6% 
(w/v) alginate and 0.12mg AuNP were implanted into the 
tumours using a modified template device. A microCT 
(Scanco Medical μCT100, Switzerland) was used to image the 
tumours ex vivo at 1, 7, 14, and 28 days post implantation. 
AuNP concentrations were determined using a radiodensity 
calibration curve. 
Results: Preliminary results indicate that alginate is an 
appropriate material for implantation and that its stability 
can be controlled by optimizing its weight to volume 
concentration. Seeds made from very low viscosity-
guluronate (VLV-G) alginate (6%, 8%, 10% wt/vol) were able 
to release AuNP into phantoms (Figure 1a). MicroCT imaging 
revealed that 6% alginate seeds released AuNP 1.4 and 1.5 
times faster than 8% and 10% seeds respectively. Preliminary 
animal data using 6% alginate seeds and 30nm AuNP also show 
local AuNP release (Figure 2a). Tumour bearing mice 
implanted with seeds retained only 67% of the initial AuNP 
amount by 28days.  
 
Conclusions: The overarching vision is to develop a novel 
form of brachytherapy using a nanoparticle based radioactive 
source that may offer a solution for improving local dose 
distribution for interstitially implanted sources. Preliminary 
data has shown that by embedding AuNPs into calcium 
alginate seeds, controlled release and diffusion can be 
achieved.  
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Purpose/Objective: APBI is currently considered a viable 
treatment option in early-stage breast cancer patients. 
Mostly due to the rising need to treat patients outside clinical 
trials, in 2009 two consensus statements (CS) were created 
by ASTRO (American Society for Radiation Oncology) and 
GEC-ESTRO (Groupe Européen de Curiethérapie-European 
Society for Radiotherapy and Oncology). More recently, 
guidelines from ABS (American Brachytherapy Society) were 
also published. This helps the train of thought Radiation 
Oncologists have to undergo concerning the decision for the 
most appropriate adjuvant radiation treatment modality in 
early-stage breast cancer patients. Nevertheless, during that 
process, doubts may emerge due to the lack of parallelism 
among the three guidelines that can lead to different risk 
group stratification/treatment indications for the same 
patient. Our study aimed at comparing the rate of suitable 
and unsuitable patients for APBI according to the three 
guidelines. As a secondary objective survival and relapse 
rates were also addressed. 
Materials and Methods: 81 patients submitted to APBI, in a 
single-institution, were retrospectively analyzed (treated 
from 2003 to 2013) and then categorized according to 
indication for treatment as 'suitable', 'cautionary' and 
'unsuitable' (ASTRO), as 'low risk', 'intermediate risk' and 'high 
risk' (GEC-ESTRO), and as 'acceptable' and 'not acceptable' 
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(ABS). Data regarding tumour, treatment technique and 
patient-related features was collected, as well as recurrence 
and survival rates. 
Results: Median follow-up time was 35,1 months, 46 patients 
underwent HDR and 35 a PDR technique either with metal 
needles or flexible plastic catheters using a template-based 
system. 75 were suitable for guideline stratification (2 
patients lost to follow-up and 6 without complete 
information about risk factors). According to the ASTRO CS, 
47 patients were considered 'suitable', 23 'cautionary' and 5 
'unsuitable'. According to GEC-ESTRO, 60 were 'low risk', 7 
'intermediate risk' and 8 'high risk'. 69 patients were defined 
as 'acceptable' and 6 as 'not acceptable' following ABS 
recommendations. 46 of ABS 'acceptable' patients were also 
either 'suitable' or 'low risk' according to ASTRO and GEC-
ESTRO, meaning an accordance rate between guidelines on 
who to definitely treat with APBI of 67%. 6% (n=4) of patients 
with clear indication not to treat by ASTRO and/or GEC-
ESTRO fitted the 'acceptable' group criteria by ABS. No loco-
regional relapses were documented, 1 patient developed 
distant metastasis. 
Conclusions: This study shows a lack of agreement between 
the current guidelines and supports the existing evidence 
that APBI with multicatheter brachytherapy is an effective 
adjuvant treatment modality. 
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Purpose/Objective: Previous health related quality of life 
(HRQL) analyses of the PORTEC-2 trial showed that women 
treated with vaginal brachytherapy (VBT) reported 
significantly less bowel symptoms compared to those treated 
with pelvic radiotherapy (EBRT). In the PORTEC-1 trial, with 
longer follow-up more urinary symptoms and use of 
incontinence materials were reported by women who 
underwent EBRT. This analysis evaluates long-term HRQL in 
PORTEC-2, focussing on long-term bowel and urinary 
symptoms. 
Materials and Methods: In PORTEC-2 427 stage I endometrial 
cancer patients with high-intermediate risk features were 
randomized between postoperative EBRT or VBT. The HRQL 
questionnaire was completed at 6-12 month intervals and at 
7 and 10 years, and consisted of the EORTC QLQ-C30, and 
subscales for bowel and bladder symptoms from PR25 and 
OV28. At 7 and 10 years questions on comorbidities, and use 
of walking aids and incontinence pads were added. 
Longitudinal analysis was performed using linear mixed 
models and the t-test was applied when comparing HRQL 
scores at specific time points 
Results: The 7-year questionnaires were sent to 265 patients 
of whom 202 (76%) responded, and 80 of 119 (67%) at 10 
years due to on-going follow-up. Longitudinal analysis showed 
persistence of increased diarrhoea, faecal leakage and 
limitations due to bowel symptoms after EBRT (all p<0.001). 
For EBRT vs. VBT at 7-years, 8.4% vs 1.8% (p=0.056) patients 
reported quite a bit or very much diarrhoea, while this was 
10.5% vs 2.7% (p=0.031) for faecal leakage and 10.3% vs 2.7% 
(p=0.002) for limitations due to bowel symptoms. 
Furthermore, longitudinal analysis found an increased need 
to remain close to the toilet (p=0.001) and a trend for more 
urinary symptoms (p=0.064): for EBRT vs. VBT at 7-years 
38.9% vs 26.1% (p=0.077) reported quite a bit or very much 
urinary urgency, 12.9% vs 7.3% (p=0.079) sleep deprivation 
due to urinary urgency and 8.2% vs 6.4% (p=0.084) need to 
remain close to the toilet. No difference in the use of 
incontinence pads for EBRT vs. VBT was found at 7 years, any 
use for urine 51.1 vs 51.9% and for defecation 18.6% vs 13.5%. 
Additional analysis of previous PORTEC-1 HRQL showed that 
increased use of any incontinence material was mainly seen 
in patients treated with parallel opposed fields (72%), 
compared to 4-field technique (50.9%) and controls (40%, 
p=0.065). 
Conclusions: Up to 7 years after treatment in the PORTEC-2 
trial, patients treated with EBRT reported more bowel 
symptoms impacting on daily activities and a trend for more 
urinary symptoms, without increased use of incontinence 
pads. The increased use of incontinence pads after 15-years 
in the PORTEC-1 trial was mainly seen in patients treated 
with parallel opposing fields, while all patients in PORTEC-2 
were treated with a 4-field technique.  
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Purpose/Objective: To analyse the correlation between total 
delivered dose from external beam radiotherapy (EBRT) and 
image guided adaptive brachytherapy (IGABT) to metastatic 
nodes and individual nodal outcome in patients with locally 
advanced cervical cancer. 
Materials and Methods: A total of 140 patients enrolled in 
the Embrace study (www.embracestudy.dk) from two 
institutions were included. Treatment consisted of EBRT, 
Cisplatin and IGABT delivered in the period 2008-2013. FIGO 
stage ranged from IB-IVA with the majority being IIB or 
higher. Eighty-three patients were lymph node positive on 
FDG PET-CT and/or MRI. Lymph nodes with a SUV above 
